CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Refractory and relapsed B acute lymphoblastic leukemia (B-ALL) presents a significant challenge in pediatric and adult cancer treatment.
• Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising approach for B-ALL, targeting antigens like CD19, CD20, and CD22.

Purpose of the Study:

• To review the efficacy of CAR-T cell therapy in B-ALL.
• To explore strategies for overcoming relapse after CAR-T therapy, including allogeneic stem cell transplantation and allogeneic CAR-T cells.

Main Methods:

• Review of recent studies on CAR-T cell therapy for B-ALL.
• Analysis of outcomes for patients undergoing CAR-T therapy, including relapse rates.
• Evaluation of consolidative strategies such as allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and allogeneic CAR-T cells.

Main Results:

• CD19 CAR-T cells achieve high complete remission rates (80-90%) in R/R B-ALL.
• Approximately 50% of patients relapse within 1-2 years post-CAR-T therapy.
• The role of Allo-HSCT as consolidation after CAR-T therapy is variable, and alternative approaches like donor-derived or allogeneic CAR-T cells are under investigation.

Conclusions:

• CAR-T cell therapy is effective for R/R B-ALL but long-term remission remains a challenge.
• Consolidation strategies, including donor-derived CAR-T cells and allogeneic CAR-T cells, are being explored to improve outcomes.
• Further research is needed to optimize CAR-T cell therapy and consolidation for B-ALL patients.